AADAPT Act

The AADAPT Act (HR3747) was ordered to be reported by the House committee on May 21, 2026, with a unanimous 48-0 vote, indicating strong bipartisan support. The bill amends the Public Health Service Act to reauthorize the Project ECHO Grant Program and establish new grants specifically for technology-enabled collaborative learning and capacity building models aimed at Alzheimer's disease and related dementias. The current status is 'awaiting floor action', meaning it has not yet passed the House or Senate. The bill authorizes grants but does not specify a dollar amount; it is an authorization-only bill, meaning actual funding requires separate appropriations bills. The mechanism is grant-making to eligible entities—primarily healthcare providers in underserved areas—to develop and expand tele-education models for healthcare professionals. This targets training for early diagnosis and provider retention. Structural winners are companies that provide healthcare workforce training technology. HealthStream ($HSTM) is a pure-play provider of learning management systems for healthcare organizations, directly positioned to benefit from increased grant-funded training programs. Other potential beneficiaries include telehealth platform providers like Amwell ($AMWL) and Teladoc ($TDOC), but their exposure is less direct. Alzheimer's drug makers such as Eli Lilly ($LLY) and Biogen ($BIIB) could see downstream benefits if training leads to increased diagnosis and treatment, but the causal chain is too weak to include with high confidence. Real market data was not provided, so no price action analysis is included. The unanimous committee vote suggests strong momentum for passage, but floor timing is uncertain. Given the authorization-only nature and lack of funding specifics, the near-term market impact is minimal, but the bill signals ongoing legislative support for Alzheimer's care infrastructure and healthcare workforce training.